EUVIMEDEUVIMED entdecken
Leitlinie

Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update

John D Gordan iD, Erin B Kennedy iD, Ghassan K Abou-Alfa iD, Eliza Beal iD, Richard S Finn iD, Terence P Gade iD, Laura Goff, Shilpi Gupta, Jennifer Guy, Hang T Hoang, Renuka Iyer iD, Ishmael Jaiyesimi und 12 weitere

Journal of Clinical Oncology · 20.05.2024 · 42 (15) · 1830-1850

DOI: 10.1200/jco.23.02745 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.05.2024. Verfasst von John D Gordan und 23 weiteren Autor:innen. Beteiligte Einrichtung: University of California, San Francisco, San Francisco, CA. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 338-mal zitiert (Crossref) und nennt 116 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE To update an evidence-based guideline to assist in clinical decision-making for patients with advanced hepatocellular carcinoma (HCC). METHODS ASCO convened an Expert Panel to update the 2020 guideline on systemic therapy for HCC. The panel updated the systematic review to include randomized controlled trials (RCTs) published through October 2023 and updated recommendations. RESULTS Ten new RCTs met the inclusion criteria and were added to the evidence base. RECOMMENDATIONS Atezolizumab + bevacizumab (atezo + bev) or durvalumab + tremelimumab (durva + treme) may be offered first-line for patients with advanced HCC, Child-Pugh class A liver disease, and Eastern Cooperative Oncology Group performance status 0-1. Where there are contraindications to these therapies, sorafenib, lenvatinib, or durvalumab may be offered first-line. Following first-line treatment with atezo + bev, second-line therapy with a tyrosine kinase inhibitor (TKI), ramucirumab (for patients with alpha-fetoprotein [AFP] ≥400 ng/mL), durva + treme, or nivolumab + ipilimumab (nivo + ipi) may be recommended for appropriate candidates. Following first-line therapy with durva + treme, second-line therapy with a TKI is recommended. Following first-line treatment with sorafenib or lenvatinib, second-line therapy options include cabozantinib, regorafenib for patients who previously tolerated sorafenib, ramucirumab (AFP ≥400 ng/mL), nivo + ipi, or durvalumab; atezo + bev or durva + treme may be considered for patients who did not have access to these therapies in the first-line setting, and do not have contraindications. Pembrolizumab or nivolumab are also options for appropriate patients following sorafenib or lenvatinib. Third-line therapy may be considered in Child-Pugh class A patients with good PS, using one of the agents listed previously that has a nonidentical mechanism of action with previously received therapy. A cautious approach to systemic therapy is recommended for patients with Child-Pugh class B advanced HCC. Further guidance on choosing between options is included within the guideline. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHumansAntineoplastic Combined Chemotherapy ProtocolsRandomized Controlled Trials as Topic

Autor:innen und Institutionen

  • University of California, San Francisco, San Francisco, CA.
  • American Society of Clinical Oncology, Alexandria, VA.
  • Memorial Sloan Kettering Cancer Center and Weill Medical College at Cornell University, New York, NY.
  • Trinity College Dublin Medical School, Dublin, Ireland.
  • Karmanos Cancer Center, Detroit, MI.
  • Geffen School of Medicine, UCLA, Los Angeles, CA.

ORCID-Profile: John D Gordan, Erin B Kennedy, Ghassan K Abou-Alfa, Eliza Beal, Richard S Finn, Terence P Gade, Renuka Iyer, Minaxi Jhawer, Asha Karippot, Ahmed O Kaseb, R Kate Kelley, Jeremy Kortmansky, Davendra P S Sohal, Tamar H Taddei, Andrea Wilson Woods, Mark Yarchoan, Michal G Rose

Zitieren

APA

Gordan, J. D., Kennedy, E. B., Abou-Alfa, G. K., Beal, E., Finn, R. S., Gade, T. P., Goff, L., Gupta, S., Guy, J., Hoang, H. T., Iyer, R., Jaiyesimi, I., Jhawer, M., Karippot, A., Kaseb, A. O., Kelley, R. K., Kortmansky, J., Leaf, A., Remak, W. M., …, & Rose, M. G. (2024). Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update. Journal of Clinical Oncology, 42(15), 1830-1850. https://doi.org/10.1200/jco.23.02745

Vancouver

Gordan JD, Kennedy EB, Abou-Alfa GK, Beal E, Finn RS, Gade TP, et al. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update. Journal of Clinical Oncology. 2024;42(15):1830-1850. doi:10.1200/jco.23.02745

BibTeX
@article{Gordan2024,
  author = {Gordan, John D and Kennedy, Erin B and Abou-Alfa, Ghassan K and Beal, Eliza and Finn, Richard S and Gade, Terence P and Goff, Laura and Gupta, Shilpi and Guy, Jennifer and Hoang, Hang T and Iyer, Renuka and Jaiyesimi, Ishmael and Jhawer, Minaxi and Karippot, Asha and Kaseb, Ahmed O and Kelley, R Kate and Kortmansky, Jeremy and Leaf, Andrea and Remak, William M and Sohal, Davendra P S and Taddei, Tamar H and Wilson Woods, Andrea and Yarchoan, Mark and Rose, Michal G},
  title = {Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {15},
  pages = {1830--1850},
  doi = {10.1200/jco.23.02745}
}
Kostenlos starten →